Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2026 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals First Quarter 2026 Earnings Conference Call.
Verrica Pharmaceuticals Inc. (VRCA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Caligan Partners David Johnson | 923,910 | $4,887,484 | 0.33% | |
| 2. | Cannell Capital J. Carlo Cannell | 685,123 | $3,624,301 | 2.23% | |
| 3. | Armistice Capital Steven Boyd | 518,181 | $2,741,177 | -54% | 0.05% |
| 4. | Velan Capital Adam Morgan | 471,559 | $2,494,547 | 1.56% | |
| 5. | DAFNA Capital Management Nathan Fischel | 153,712 | $813,136 | -12% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.24 | 2,357 | $9,999.57 | 2,357 | 2025-11-25 | Filing | |
| $4.24 | 3,536 | $15,001.48 | 8,962 | 2025-11-25 | Filing | |
| $4.24 | 10,000 | $42,425.00 | 21,000 | 2025-11-25 | Filing | |
| $4.24 | 94,311 | $400,114.42 | 182,593 | 2025-11-25 | Filing | |
| $4.24 | 2,750,762 | $11,670,107.79 | 3,348,372 | 2025-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 4,315 | $2,804.75 | 176,458 | 2025-03-17 | Filing | |
| $2.46 | 9,530 | $23,443.80 | 105,773 | 2024-08-27 | Filing | |
| $2.66 | 26,183 | $69,646.78 | 115,303 | 2024-08-26 | Filing | |
| $2.46 | 3,601 | $8,858.46 | 94,261 | 2024-08-27 | Filing | |
| $2.66 | 9,888 | $26,302.08 | 97,862 | 2024-08-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 707,338 | $3,741,818 | 0.19% | |
| 2. | 280,734 | $1,485,083 | 0.02% | |
| 3. | 188,758 | $998,530 | 0% | |
| 4. | 138,917 | $734,965 | 0% | |
| 5. | 65,101 | $344,384 | 0% |
News See All
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Second Quarter 2025 Corporate Update Conference Call.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals’ Fourth Quarter and Full Year 2024 Corporate Update Conference Call.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.47. Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Hedge Fund and Insider Trading News: Paul Marshall, Crispin Odey, Point72 Asset Management, Asgard Fixed Income Fund, Brookfield Hedge Solutions Advisors, B Riley Financial Inc (RILY), Verrica Pharmaceuticals Inc. (VRCA), and More
GB News owner Sir Paul Marshall’s hedge fund has made a multi-million pound gain on its bet against NatWest shares following the exit of Dame Alison Rose.
Hedge Fund Resource Center